Document ID: chunk:federal_register_of_legislation:F2024L01335:front:0:p4
Version: federal_register_of_legislation:F2024L01335
Segment Type: other
Provision Reference: 
Character Range: 9290–13048

the affected trigeminal nerve, at the time of clinical onset or clinical worsening;
Note: Examples of a mass lesion that can compress, displace or infiltrate the trigeminal nerve include a benign or malignant neoplasm, haematoma, abscess, granuloma, amyloidoma, cyst or benign fibro-osseous lesion.
 1.       having cervical disc prolapse or cervical syringomyelia, involving the cervical spine at C4 or above, at the time of clinical onset or clinical worsening of trigeminal neuropathy;
 2.       having one of the following inflammatory connective tissue diseases:
         1.           mixed connective tissue disease;
         2.           Sjögren syndrome;
         3.           systemic lupus erythematosus;
         4.           systemic sclerosis (scleroderma);
at the time of clinical onset or clinical worsening;
 1.       having rheumatoid arthritis or sarcoidosis at the time of clinical onset or clinical worsening of trigeminal neuropathy;
 2.       having one of the following systemic vasculitides:
         1.           Behçet disease;
         2.           eosinophilic granulomatosis with polyangiitis (Churg-Strauss syndrome);
         3.           giant cell arteritis;
         4.           granulomatosis with polyangiitis (Wegener granulomatosis);
         5.            polyarteritis nodosa;
         6.            Takayasu arteritis;
at the time of clinical onset or clinical worsening of trigeminal neuropathy;
 1.       having invasive bacterial or fungal paranasal sinusitis or viral meningoencephalitis, at the time of clinical onset or clinical worsening of trigeminal neuralgia;
 2.       having one of the following infections involving the affected trigeminal nerve, at the time of clinical onset or clinical worsening of trigeminal neuropathy:
         1.           abscess;
         2.           Lyme disease (Borrelia burgdorferi infection);
         3.           brainstem meningitis or encephalitis;
         4.           herpes simplex virus infection;
         5.           invasive bacterial or fungal sinusitis;
         6.            leprosy (Mycobacterium leprae infection);
         7.           odontogenic infection;
         8.           osteomyelitis;
         9.             suppurative otitis media;
        10.             syphilis (Treponema pallidum infection);
 3.       having acute herpes zoster involving the affected trigeminal nerve, within the 1 year before clinical onset or clinical worsening of trigeminal neuropathy;
 4.       having infection with human immunodeficiency virus at the time of clinical onset or clinical worsening of trigeminal neuropathy;
 5.       having multiple sclerosis at the time of clinical onset or clinical worsening;
 6.       having Charcot–Marie–Tooth disease at the time of clinical onset or clinical worsening of trigeminal neuralgia;
 7.       having a cerebrovascular accident (stroke) involving the brainstem within the 30 days before clinical onset or clinical worsening;
 8.       having diabetes mellitus at the time of clinical onset or clinical worsening of trigeminal neuropathy;
 9.       being treated with one of the following medications:
         1.           cisplatin;
         2.           hydroxystilbamidine isethionate (stilbamidine);
         3.           vincristine;
for a continuous period of at least 7 days, within the 3 months before clinical onset or clinical worsening of trigeminal neuropathy;
 1.       inhaling, ingesting or having cutaneous contact with trichloroethylene on at least 30 occasions, within the 6 months before clinical onset or clinical worsening of trigeminal neuropathy;
 2.       having an episode of acute intoxication, from inhaling, ingesting or having cutaneous contact with trichloroethylene or ethylene